It increases insulin release after meals and lowers glucagon release, so the liver makes less glucose
Hernndez-Saavedra D, Hinkley JM, Baer LA, Pinckard KM, Vidal P, Nirengi S, et al
The molecule is structurally modified with an N-terminal trans-3-hexenoyl group, which dramatically reduces its susceptibility to dipeptidyl peptidase IV (DPP-IV) degradation, the enzyme that breaks down natural GHRH
Through clinical research and practice, they gradually realized the medicinal value of BC and began using it in clinical settings
Discontinuation rates tell the real story Perhaps the most telling safety metric is not which side effects occur but how many people stop treatment because of them
This compound has been found in concentrated amounts in the milk of lactating rats